AC Immune SA ACIU
1.95 USD -0.18 (-8.45%)
Regular-session close
1.95 0.00 0.00%
After hours · Nov 20, 6:35 PM ET
1.93 Day range 2.15
1.95 52-week range 3.70
- YTD
- -37.90%
- 1 year
- -32.99%
News
globenewswire.com AC Immune to Present at Jefferies Global Healthcare Conference 2026 AC Immune to Present at Jefferies Global Healthcare Conference 2026 Lausanne, Switzerland, November 11, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharma company targeting the key…
zacks.com AC Immune (ACIU) Reports Q3 Loss, Beats Revenue Estimates AC Immune (ACIU) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.2 per share a year ago.benzinga.com AC Immune Q3 EPS $(0.16) Beats $(0.22) Estimate, Sales $3.994M Beat $1.000M Estimate AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.22) by 27.27 percent. This is a 20 percent increase over losses of $(0.20) per…
globenewswire.com AC Immune Third Quarter 2026 Financial and Corporate Update AC Immune announces financial and corporate updates for the quarter ended September 30, 2026, with positive progress across its wholly-owned pipeline.
zacks.com Best Momentum Stock to Buy for September 30th SCL and ACIU made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 30, 2026.
marketbeat.com AC Immune Parkinson's Vaccine Study Meets Safety, Immunogenicity Goals AC Immune NASDAQ: ACIU reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson's…
seekingalpha.com AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions AC Immune maintains a "Buy" rating, driven by positive 100-week safety and immunogenicity data for ACI-7104 in early-stage Parkinson's disease. Progress in the pipeline includes Takeda-partnered…
globenewswire.com AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104 All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated Strong immunogenicity demonstrated, with 100% response rate after three immunizations Clear…
globenewswire.com AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 AC Immune announced positive interim Phase 1 results from a first-in-human clinical study evaluating ACI-19764, an NLRP3 inhibitor targeting inflammation.
zacks.com AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates AC Immune (ACIU) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to a loss of $0.25 per share a year ago.
globenewswire.com AC Immune First Half 2026 Financial and Corporate Update AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key…
globenewswire.com AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC ® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical…
globenewswire.com AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease ACI-24 anti-Abeta active immunotherapy generally safe and well tolerated in first three…
globenewswire.com AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104 Planned extension of…
zacks.com AC Immune (ACIU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? AC Immune (ACIU) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a…
globenewswire.com AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients…
globenewswire.com Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care
zacks.com AC Immune (ACIU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now AC Immune (ACIU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among…
globenewswire.com AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure Board Chair, Martin Zügel, MD, to be…
zacks.com AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates AC Immune (ACIU) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.21 per share a year ago.
globenewswire.com AC Immune First Quarter 2026 Financial and Corporate Updates AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy…
